Pfizer Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Pfizer will hold a meeting of the Board of Directors of the Company on 9 February 2026.

Powered by Capital Market - Live News

Pfizer announced the following change in senior management:

• Nilesh Pendse is appointed as Category Lead - Vaccines of the Company with effect from 01 February 2026. Pendse shall accordingly be a Senior Management Personnel of the Company effective the said date.
• Manikantan Seshadrinathan - Category Lead, Hospitals & Rare Disease will transition to another role within the Pfizer Group Companies effective 01 February 2026, and shall accordingly cease to be a Senior Management Personnel of the Company effective 31 January 2026.
• Prashant Mahalingam, Category Lead - Internal Medicine, will take up additional responsibility of the Hospitals Business of the Company and shall be redesignated as Category Lead - Internal Medicine & Hospitals, effective 01 February 2026.

Powered by Capital Market - Live News

Pfizer has entered into an exclusive Supply and Marketing Agreement with Cipla for marketing and distribution of four brands of the Company, viz., Corex Dx, Corex LS, Dolonex, and Neksium for an initial period of 5 years.

Powered by Capital Market - Live News

On a standalone basis, net sales stood at Rs 642.34 crore, rising 9.1% year-on-year from Rs 588.59 crore in Q2 FY25 and 6.5% sequentially from Rs 603.05 crore in Q1 FY26.

Net profit (PAT) rose 19.4% YoY to Rs 189.02 crore, compared with Rs 158.35 crore in Q2 FY25, as current tax expense increased 9.4% to Rs 65.49 crore. Sequentially, PAT was down 1.4% from Rs 191.75 crore in Q1 FY26.

Profit before tax (PBT) climbed 18.7% YoY to Rs 255.37 crore, though slightly lower by 1.6% QoQ.

Total expenditure inched up 3.3% YoY and 4.9% QoQ to Rs 412.41 crore. Raw material costs declined 8.7% YoY to Rs 70 crore, while employee expenses fell 6% YoY to Rs 94.67 crore. Depreciation stood at Rs 14.28 crore, down 4.74% year-on-year, while interest expenses were steady at Rs 2.13 crore.

Net cash flow from operating activities stood at Rs 599.47 crore in H1 FY26, as against a cash flow of Rs 349.43 crore in H1 FY25.

Pfizer is engaged in manufacturing, marketing, trading and export of pharmaceutical products.

Powered by Capital Market - Live News